Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 160

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 160
---
, and there can be no assurance that Nugevia will achieve market acceptance or generate anticipated
sales. If we fail to execute the launch effectively, experience delays in product availability, or encounter challenges in maintaining
product quality and regulatory standards, our ability to establish Nugevia as a recognized and trusted brand may be compromised.

Additionally,
the introduction of Nugevia may provoke competitive responses from established market participants, potentially resulting in increased
pricing pressure or heightened marketing costs. If the Nugevia brand does not gain sufficient traction or if we are unable to recover
our investment in its development and promotion, our growth prospects and overall financial performance could be negatively impacted.

Our
business and future prospects with the Nugevia brand and our pharmaceutical products are significantly dependent on our exclusive, worldwide
license agreement with Aquanova. Any adverse development related to this license agreement could materially and adversely affect our
operations, financial condition, and results of operations.

Our
business and future prospects are significantly dependent on our exclusive, worldwide license agreement with Aquanova AG, which grants
us rights to develop, manufacture, distribute, and sell key products, including JOTROL™. Any adverse development related to this
agreement could materially and adversely affect our operations, financial condition, and results of operations

If
the license agreement with Aquanova AG were to be terminated, limited, or materially altered, we could lose access to essential proprietary
technologies, such as Aquanova’s NovaSOL® formulation technology, which is critical for the bioavailability and effectiveness
of our Nugevia brand. Disputes over contract terms, intellectual property rights, or performance obligations could result in costly litigation,
delays in product development, or loss of commercialization rights. Additionally, our obligation to pay license fees and royalties under
the license agreement represents a significant financial commitment, and any inability to meet these obligations could jeopardize our
rights under the license agreement. The loss or impairment of this license would require us to seek alternative technologies or partners,
which may not be available on favorable terms, if at all, and could delay or prevent the development and commercialization of our products.

Should
we fail to maintain a productive relationship with Aquanova or if Aquanova experiences operational or financial difficulties, our ability
to deliver products to market could be compromised, negatively impacting our growth prospects and competitive position.

If
the Company or its suppliers fails to comply with FDA or other regulations, it could result in enforcement actions or delays in the Nugevia
brand product launch.

The